The advent of single-administration cell and gene therapies (CGTs) has the potential to change the landscape of modern medicine. However, these therapies are accompanied by significant costs and other uncertainties that complicate risk assessment and forecasting for healthcare payers and plan sponsors. This white paper discusses:

• The current landscape of single-administration CGTs
• Key factors driving unpredictability in CGT utilization and costs
• Approach to estimating CGT case and cost exposure
• Episodic costs for CGTs from a commercial claims analysis
• Best practices for evaluating CGTs